Revolution Medicines
12 stories related to this topic, newest first.
zmescience.comJohnson & Johnson to Acquire KRAS Startup Firefly Bio for $1 Billion After Recent Pancreatic Cancer Data Validates Field
The acquisition targets KRAS inhibitors after Revolution Medicines reported nearly doubled survival in metastatic pancreatic cancer less than two months earlier.
StatPatient Reports Benefit from Revolution Medicines’ Daraxonrasib as Oncologists Applaud Data but Biotech Stocks Fall
Leanna Stokes, diagnosed with metastatic pancreatic cancer in 2023, discussed her experience in a Revolution Medicines clinical trial on a June 4, 2026 podcast. Oncologists gave a standing ovation to data on the company’s drug daraxonrasib presented at last week’s American Societ…
finance.yahoo.comRevolution Medicines Offers Daraxonrasib via Expanded Access Program After Positive Pancreatic Cancer Trial
Amy Johnston, 35, diagnosed in 2025, awaits results from a clinical trial by end of June 2026 and may pursue daraxonrasib if unsuccessful. The drug nearly doubled survival in trials but faces production and access delays.
winnipegfreepress.comRevolution Medicines pancreatic cancer drug advances toward second-line use
Daraxonrasib is positioned to become the standard second-line treatment for pancreatic cancer. Questions remain about its potential use in newly diagnosed patients.
benzinga.comRevolution Medicines Reports Pancreatic Cancer Drug Data at ASCO
New results for Revolution Medicines' daraxonrasib were presented at the ASCO conference over the weekend. A pancreatic cancer expert described an emotional reaction after treating patients with the data.
Substrate placeholder — needs reviewRevolution Medicines Presents Strong KRAS Drug Data and Preclinical Compound Insights
Revolution Medicines shared clinical trial success for its pancreatic cancer therapy last week and preclinical data on a new compound yesterday. The company also presented strong results for its KRAS drug at the AACR meeting on April 21, 2026. Additional biotech developments incl…
news.google.comRevolution Medicines Reports Extended Survival in Pancreatic Cancer Trial
Revolution Medicines announced results from a Phase 3 study of its experimental drug daraxonrasib for advanced pancreatic adenocarcinoma. Patients treated with the drug had a median survival of 13.2 months, compared to 6.7 months for those on standard chemotherapy. The company pl…
France 24Revolution Medicines' Daraxonrasib Trial Reports 13.2-Month Median Survival in Pancreatic Cancer Patients
Revolution Medicines announced results from a late-stage trial of its experimental oral drug daraxonrasib for pancreatic cancer patients. Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those on standard intravenous cytotox…
Substrate placeholder — needs reviewRevolution Medicines' Daraxonrasib Succeeds in Phase 3 Trial for Pancreatic Cancer
Revolution Medicines announced that its targeted pill daraxonrasib met primary and secondary endpoints in a Phase 3 trial for metastatic pancreatic cancer patients. The drug extended median survival to 13.2 months compared to 6.7 months with chemotherapy and reduced the risk of d…
Substrate placeholder — needs reviewRevolution Medicines' Daraxonrasib Succeeds in Phase 3 Pancreatic Cancer Trial
Revolution Medicines announced that its drug daraxonrasib met primary and secondary endpoints in a Phase 3 trial for pancreatic cancer patients whose disease had progressed on prior treatment. The trial showed a median overall survival of 13.2 months for daraxonrasib compared to…
dailywire.comFormer Senator Ben Sasse Undergoes Treatment with Revolution Medicines' Daraxonrasib for Pancreatic Cancer
Former U.S. Senator Ben Sasse is receiving daraxonrasib, an experimental drug developed by Revolution Medicines, as a treatment for pancreatic cancer. The drug has demonstrated potential effectiveness in early clinical trials for this disease. Sasse's involvement highlights ongoi…
Substrate placeholder — needs reviewRevolution Medicines Advances Testing of Pancreatic Cancer Treatment Pill
Revolution Medicines is conducting clinical trials for a pill targeting pancreatic cancer. The treatment aims to address a disease with limited effective options. CNBC reported on the company's latest developments in this area.